Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01644279 · ClinicalTrials.gov registry record

Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle

A clinical trial of Sarcopenia, sponsored by University of Florida.

Completed
Registry status
63
Enrollment target
1
Study location

NCT01644279: Completed study of Sarcopenia, sponsored by University of Florida.

NCT01644279 is a study of Sarcopenia that has completed, run by University of Florida. The registered enrollment target is 63 participants, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01644279, a study of Sarcopenia, has completed, sponsored by University of Florida.

COMPLETED
Registry status
63 participants
Enrollment target
1
Study location

Study Summary

The age-related loss of muscle mass and strength, also termed sarcopenia, is a commonly recognized consequence of aging and has been associated with frailty, functional loss, hospitalization, and increased mortality among older people. Sarcopenia and its consequences have a considerable economic impact, since it has been estimated that the healthcare cost attributable to sarcopenia in the US in 2000 was $ 18.5 billions. Preclinical animal models strongly suggest that apoptosis, a programmed cell death, might play a prominent role in the age-related muscle wasting. In specific aim one, the investigators will assess the extent of muscle apoptosis in muscle biopsies obtained from the vastus lateralis muscle of young control subjects (ages 20-35) and high-performance and low-performance older subjects (age range 70-99 years). In specific aim 2, the investigators will investigate the role of Poly (ADP-ribose) polymerase 1 (PARP-1) and apoptosis-inducing factor (AIF) in the induction of skeletal muscle apoptosis. In specific aim 3, the investigators propose to investigate the contribution of the muscle energy deficit, due to the age-related mitochondrial dysfunction, in the development of muscle wasting. Finally, in specific aim 4, the investigators propose to reassess after four years physical performance, muscle mass and the extent of muscle apoptosis, in the high-performing participants, in order to correlate eventual decline in physical function, muscle mass and functional status, with changes in muscle apoptosis and in biochemical parameters in this very old population. Physical performance will be established according to the summary performance score obtained in the Short Form Physical Performance Battery (SPPB). In addition to the SPPB the investigators will also employ hand grip strength and knee extensor strength tests and the investigators will quantify muscle contractile area using 3D magnetic resonance imaging. Disability will be assessed using a self-report

Primary Outcome

The SPPB is composed by three subtasks: usual gait speed, standing balance and chair stand tests.

Conditions Studied

Study Locations (1)

Florida

  • University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2006-03
Est. Completion 2016-07
University of Florida

1,106 total trials

What the finished NCT01644279 record still lists

NCT01644279 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (20% lower).

The record links to 1 condition, with Sarcopenia appearing as the primary indexed condition, and to 0 interventions.

NCT01644279 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT01644279 about?

NCT01644279 is a clinical study titled "Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle". The age-related loss of muscle mass and strength, also termed sarcopenia, is a commonly recognized consequence of aging and has been associated with frailty, functional loss, hospitalization, and increased mortality among older people. Sarcopenia and its consequences have a considerable economic imp...

What is the current status of trial NCT01644279?

This trial is currently completed. The enrollment target is 63 participants. The study started on 2006-03. Estimated completion is 2016-07.

What conditions does trial NCT01644279 study?

This clinical trial studies the following conditions: Sarcopenia.

Who is sponsoring clinical trial NCT01644279?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01644279 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01644279's enrollment target sits among peer trials

63 20th of 41 higher than 22 of 41 other Sarcopenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sarcopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03383575 · 63 participants · Phase 2

    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • NCT04870944 · 63 participants · Phase 1

    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • NCT05031897 · 63 participants · Phase 2

    Two Step Haplo With Radiation Conditioning

  • NCT05312671 · 63 participants · Phase 2

    Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01644279, the US trial registry maintained by the National Library of Medicine. NCT01644279 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.